drugset / Trial / NCT04910126
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
Phase 2
Unknown
84 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of the combination of adriamycin and Camrelizumab in the first-line treatment of advanced soft tissue sarcoma
Timeline
- Start
- 2020-11-12
- Primary completion
- 2023-01-12
- Completion
- 2023-11-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Doxorubicin | Other / unclassified | 20 mg/m2 | — |